MedTrace Logo

Intensive Vasodilator Therapy in Patients With Essential Hypertension

NCT01180413 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2012-04-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether add-on of intensive vasodilator therapy can improve the coronary perfusion and reduce the total peripheral resistance in patients with ongoing treatment for essential hypertension.

Conditions

Interventions

DRUG

Amlodipine

5 mg per day for 6 months as add-on to original ongoing antihypertensive treatment

DRUG

Ramipril

5 mg per day for the first to weeks as add-on to original ongoing antihypertensive treatment. Then upward adjustment to 10 mg per day for 6 months if no intolerable side effects are experienced.

DRUG

Lercanidipine

Up to 20 mg per day for 6 months as add-on to original ongoing antihypertensive treatment

DRUG

Losartan

Up to 100 mg per day for 6 months as add-on to original ongoing antihypertensive treatment

Sponsors & Collaborators

  • University of Aarhus

    collaborator OTHER

  • Aarhus University Hospital

    lead OTHER

Principal Investigators

  • Morten Engholm Pedersen, MD · Aarhus University and Aarhus University Hospital

  • Ole Norling Mathiasen, MD, PhD · Aarhus University and Aarhus University Hospital

  • Niels Henrik Buus, DMSc · Aarhus University and Aarhus University Hospital

  • Ashkan Eftekhari, MD, PhD · Aarhus University and Aarhus University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01180413 on ClinicalTrials.gov